MAZE Stock Forecast & Price Target

Maze Therapeutics is supported by early clinical evidence that directly aligns with a viable accelerated-approval path in APOL1-mediated kidney disease, where PARASOL showed a ≥50% UPCR decline at 12 months reduced kidney-failure risk by 68% and also translated into about 3.2 mL/min/yr slower eGFR loss. The company’s MZE829 program looks especially compelling because HORIZON showed a mean 35.6% uACR reduction across efficacy-evaluable patients, a 48.6% reduction in non-diabetic patients, a clean tolerability profile, and no serious adverse events, while updated data are expected in 4Q26. Investors also have multiple shots on goal from MZE782, whose Phase 1 PK profile and 39-fold to 42-fold urinary Phe excretion gains support best-in-class potential in PKU, while the partnered S-606001 program adds further financial optionality.

Maze Therapeutics is viewed as fundamentally challenged because its value depends heavily on only two early programs, MZE782 and MZE829, both of which still face binary clinical, regulatory, and commercial outcomes in chronic kidney disease. The recent VRTX APOL1-mediated kidney disease data, including -43% and -17% proteinuria reductions in two cohorts, raises competitive pressure and highlights how Maze must still prove differentiated efficacy and safety, while rivals such as VRTX and Otsuka already occupy the space. Although the April registered offering lifted cash to $495M and extended runway into 2029, the company will likely need additional external funding, and any failure to secure it or to meet peak revenue assumptions could materially impair execution.